

**Date and Time:** *Friday 22<sup>nd</sup> November 2013, 10:00-16:00*

**Minutes:**

**Guideline Development Group Meeting 11 Lipid Modification (update)**

**Place:** *Boardroom, NCGC Office*

<b>Present:</b>	Anthony Wierzbicki (Chair)	(Present for notes 1 – 6)
	Lindsay Banks (Pharmacist)	(Present for notes 1 – 6)
	Liz Clark (Patient/carer member)	(Present for notes 1 – 6)
	Martin Duerden (General practitioner)	(Present for notes 1 – 6)
	Michael Khan (Diabetologist)	(Present for notes 2 – 6)
	Emma McGowan (Nurse Specialist)	(Present for notes 1 – 6)
	Dermot Neely (Chemical pathologist and lipidologist)	(Present for notes 1 – 6)
	Nadeem Qureshi (General practitioner)	(Present for notes 1 – 6)
	Alan Rees (Metabolic/general medicine/elderly care physician)	(Present for notes 1 – 6)
	Martin Harker (Health economist)	(Present for notes 1 – 6)
	Norma O'Flynn (Clinical director)	(Present for notes 1 – 6)
	David Wonderling (Health economics lead)	(Present for notes 1 – 6)

**In attendance:**

NICE Staff:		
Annette Mead	Editor	
Caroline Keir	Guideline commissioning manager	

**Observers:**

Kim Archer	Project Manager, NCGC	
Stephen Ward	Health Economist, NICE	

## Notes

1. The Chair welcomed the group to the eleventh meeting of this GDG. Apologies were received from Rajai Ahmad, Eleanor Grey, Lina Gulhane, Silvia Rabar & Angela Cooper.

The Chair asked all GDG members to declare any relevant conflicts of interest. The following interests were declared:

- **Anthony Wierzbicki** – I have contributed to the production of the International Familial Hypercholesterolemia guideline. I am a Panel member for the American Heart Association which is producing a future perspective and guideline for the management of Familial Hypercholesterolemia
- **Emma McGowan** - I have been involved in the making of a video by ITN on behalf of AstraZeneca and Herat UK on Familial Hypercholesterolemia
- **Alan Rees** – I am a member of the Joint British Societies Guidelines on Prevention of Cardiovascular Disease (JBS3) writing committee and am a trustee of Heart UK  
Dermot Neely I was involved in the development of a statement on behalf of Heart UK on lipids produced two years ago. I have been asked to attend a follow up meeting on 4<sup>th</sup> December. I was involved in the production of lipid lowering guideline produced for the North East (FATS).
- **Martin Duerden** – I have been asked to review the North Wales, Lipid lowering guideline.
- **Liz Clark** - I have been involved in two NICE guidelines – Chest Pain & Stable Angina. Also attended one meeting of Hypertension quality Standard; Diagnostic Advisory Committee - Cardiac Biomarkers.
- **Nadeem Quershi** - I have been involved in two NICE guidelines – Familial Hypercholesterolemia & Familial Breast Cancer. I am on the quality standard group for Familial Hypercholesterolemia. I am on the QAF group for NICE and lead their economics sub-group. I have been asked to give a talk on identifying FH at Heart UK in July 2014

The declarations were considered personal non-pecuniary and all members took part in the meeting

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting. The Chair informed the GDG that we would not have access to IPD data to inform the analysis
3. The Chair introduced Norma O'Flynn, clinical director at NCGC, who gave a summary of the clinical evidence review for statin therapy. The Chair thanked Norma O'Flynn for her presentation.
4. The Chair introduced Martin Harker, health economist at NCGC, who gave a presentation on the outline of the health economic model. The GDG discussed and agreed the recommendations for use of statins during primary care, secondary care and primary care prevention. The Chair thanked Martin Harker for his presentation.
5. Review of recommendations: The GDG reviewed all the recommendations that had been

## Notes

drafted so far to make sure they are in line with the evidence and to clarify the wording.

6. There were no other businesses to discuss. The Chair closed the meeting and thanked everybody for attending.

### **Date, time and venue of the next meeting:**

4 April 2014, 10:00-16:00, at the National Clinical Guideline Centre, Boardroom, 180 Great Portland Street, London W1W 5QZ